Kidney Week

Abstract: SA-PO0341

Relative Frequency of Treatment Modality, Mortality, and Hospitalization Causes in Patients on Dialysis Across 41 Countries and Five Global Regions: A MONDO Initiative Report

Session Information

• Dialysis: Epidemiology and Facility Management
  November 08, 2025 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Dialysis

• 801 Dialysis: Hemodialysis and Frequent Dialysis

Authors

• Alvarez-Elias, Ana Catalina, Fresenius Medical Care, Clinical Research, Global Medical Office, North America, New York, New York, United States

Ana Catalina Alvarez-Elias, MD, MS, MSc, PhD

• Rigodon, Vladimir, Renal Research Institute, New York, New York, United States

Vladimir Rigodon

• Jiao, Yue, Renal Research Institute, New York, New York, United States

Yue Jiao, PhD

• Guedes, Murilo Henrique, Pontifícia Universidade Catolica do Paraná, Paraná, Brazil

Murilo Henrique Guedes, MD, PhD

• Tiv, Sophanny, University of Alberta, Edmonton, Alberta, Canada

Sophanny Tiv

• Peters, Vincent, Catharina Ziekenhuis, Eindhoven, NB, Netherlands

Vincent Peters, PhD

• Wolf, Melanie, Renal Research Institute, New York, New York, United States

Melanie Wolf

• Croft, Kaitlyn Renee, Renal Research Institute, New York, New York, United States

Kaitlyn Renee Croft, MSc

• Carioni, Paola, Renal Research Institute, New York, New York, United States

Paola Carioni

• Winter, Anke, Renal Research Institute, New York, New York, United States

Anke Winter, MD

• Neri, Luca, Renal Research Institute, New York, New York, United States

Luca Neri, MD, PhD

• Chaudhuri, Sheetal, Renal Research Institute, New York, New York, United States

Sheetal Chaudhuri, PhD

• Nikam, Milind, Fresenius Medical Care Asia Pacific Ltd, Singapore, Singapore

Milind Nikam, MD, MBBS

• Toffelmire, Edwin B., Queens University, Departments of Medicine (Nephrology) and Biomedical and Molecular Sciences (Pharmacology and Toxicology), Kingston, Ontario, Canada

Edwin B. Toffelmire, MD, MSc

• Konings, Constantijn, Catharina Ziekenhuis, Eindhoven, NB, Netherlands

Constantijn Konings, MD, PhD

• Stuard, Stefano, Fresenius Medical Care Deutschland GmbH, Bad Homburg, HE, Germany

Stefano Stuard, MD, PhD

• Hussein, Rasha, Fresenius Medical Care, Clinical Research, Global Medical Office, North America, New York, United States

Rasha Hussein, MD, PhD

• Guinsburg, Adrian M., Fresenius Medical Care Deutschland GmbH, Bad Homburg, HE, Germany

Adrian M. Guinsburg, MD

• Pellizzari, Caio, Santa Casa de Curitiba, Curitiba, PR, Brazil

Caio Pellizzari, MD

• Moraes, Thyago Proença de, Pontifícia Universidade Catolica do Paraná, Paraná, Brazil

Thyago Proença de Moraes, MD, PhD

• Ye, Xiaoling, Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, United States

Xiaoling Ye, PhD, MPH

• Larkin, John W., Renal Research Institute, New York, New York, United States

John W. Larkin, PhD

• Kotanko, Peter, Renal Research Institute, New York, New York, United States

Peter Kotanko, MD, FASN

• Raimann, Jochen G., Fresenius Medical Care, Clinical Research, Global Medical Office, North America, New York, New York, United States

Jochen G. Raimann, MD, PhD, MPH

Group or Team Name

• MONDO Initiative.

Background

This study aims to describe treatment modality, mortality, and hospitalization causes using a large international database from nine providers

Methods

We present descriptive data from the MONDO Initiative, an academic-industry partnership collected anonymized data from multiple providers between 2000 and 2019. Data anonymization was performed in alignment with recommendations from a re-identification risk determination (Privacy Analytics, Ontario, CA). MONDO has U.S.-based ethics approval hosted by the Renal Research Institute

Results

We report data on 292,531 dialysis patients from 41 countries across five regions: North America (6.4%), Latin America (33.4%), Europe (45.6%), Asia-Pacific (10.4%), and Africa/Other (4.2%). Of these, 172,301 (58.9%) were male. Age distribution (in years) was as follows: 0–17 (0.13%), 18–44 (1.5%), 45–64 (17.3%), 65–74 (38.3%), and ≥75 (23.6%). Self-reported ethnicity was unavailable for 39.3%, when 42.5% identified as White, 13.4% as Other, 3.8% as Black, and 1.1% as Asian. Across the follow-up period, 103, 380, 638 treatments were performed, mostly hemodialysis (56%), followed by hemodiafiltration (35.3%), and peritoneal dialysis (8.3%). The five leading causes of death were1) cardiovascular disease (41.2%), 2) circulatory disease (38.9%), 3) infectious disease (12.1%), 4) respiratory disease [non-infectious] (5.8%), and 5) cerebrovascular disease (5.3%). While the five leading causes for hospitalization were 1) circulatory disease (9%), 2) genitourinary disease (5.7%), 3) infectious disease (5.3%), 4) respiratory disease [non-infectious] (3.9%), and digestive disease (3.4%). Other causes accounted for smaller portion of events, not detailed in this abstract

Conclusion

Our study presents one of the largest international cohorts of dialysis-dependent patients, with broad regional representation, including countries lacking formal registries. It contrasts with existing data and underscores the value of global registries for comprehensive population insights

Digital Object Identifier (DOI)

• doi: 10.1681/ASN.2025d2q2evfk